• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2020, Vol. 22 ›› Issue (2): 172-176.DOI: 10.3969/j.issn.1671-2587.2020.02.015

• 临床检验 • 上一篇    下一篇

低分子肝素治疗AECOPD合并呼吸衰竭的疗效、凝血指标、CK-MB及炎性因子表达的临床观察

程继勇, 谭家明, 李军文   

  1. 271103 新汶矿业集团莱芜中心医院重症医学科
  • 收稿日期:2018-10-14 出版日期:2020-04-20 发布日期:2020-04-16
  • 作者简介:程继勇(1982-),男,山东泰安人,主治医师,本科,主要从事呼吸重症方面研究,(Tel)13963468003。

Clinical Observation of Low Molecular Weight Heparin in the Treatment of AECOPD Combined with Respiratory Failure, Coagulation Index, CK-MB and Inflammatory Factors Expression

CHENG Ji-yong, TAN Jia-ming, LI Jun-wen   

  1. Department of critical care medicine, Laiwu Central Hospital of Xinwen Mining Group,Laiwu 271103
  • Received:2018-10-14 Online:2020-04-20 Published:2020-04-16

摘要: 目的 评估低分子肝素治疗慢性阻塞性肺疾病急性加重期(AECOPD)合并呼吸衰竭的临床疗效以及对患者凝血功能、肺功能、心肌损伤指标及炎性因子表达水平的影响。方法 选取本院2015年1月~2017年1月间收治的86例AECOPD患者为研究组,将入选患者随机均分为对照组与观察组,对照组采取常规治疗,观察组在采取常规治疗的同时给予低分子肝素治疗;治疗7天后评估并对比两组临床疗效,观察患者的肺功能指标、凝血功能指标、炎性因子及心肌损伤指标的变化情况。结果 观察组总有效率为97.67%,对照组总有效率为86.05%;观察组临床疗效较对照组理想,P<0.05。治疗后两组患者的肺功能、凝血功能指标、炎性因子及心肌损伤指标均较治疗前有所好转,P<0.05;但治疗后观察组患者各项指标均优于对照组,P<0.05。结论 低分子肝素可提高AECOPD并呼吸衰竭患者的临床疗效,降低其炎性因子表达水平,改善肺功能与过度凝血状态并减轻心肌损伤。

关键词: 慢性阻塞性肺疾病, 呼吸衰竭, 低分子肝素, 凝血功能, 肺功能, 炎性因子, 心肌损伤

Abstract: Objective To evaluate the low molecular weight heparin in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated with respiratory failure clinical curative effect and influence on blood coagulation function, pulmonary function, myocardial injury index and inflammatory factor expression. Methods 86 cases of AECOPD patients in our hospital from January 2015 to January 2017 were enrolled as the study group, the patients were randomly divided into control group and observation group, the control group received routine treatment, the observation group in the control group treatment at the same time give low molecular weight heparin; after 7d treatment to evaluate and compare the clinical efficacy of two groups, their lung function index, blood coagulation index, inflammatory factors and myocardial damage index were recorded and analysed. Results The total effective rate of the observation group was 97.67%, and that of the control group was 86.05%. The clinical efficacy of the observation group was better than that of the control group, P<0.05. After treatment, the two groups of patients were better improved in pulmonary function, coagulation function indicators, inflammatory factors and myocardial damage indicators compared to before treatment, P<0.05; but after treatment, the observation group patients were better improved than the control group, P<0.05. Conclusion Low molecular weight heparin can improve the clinical efficacy of AECOPD and respiratory failure patients, reduce the expression level of inflammatory factors, improve the pulmonary function and excessive coagulation state, and reduce myocardial injury.

Key words: Chronic obstructive pulmonary disease, Respiratory failure, Low molecular weight heparin, Coagulation function, Pulmonary function, Inflammatory factors, Myocardial injury

中图分类号: